Lymphocytes from rheumatoid arthritis patients have elevated levels of intracellular peroxiredoxin 2, and a greater frequency of cells with exofacial peroxiredoxin 2, compared with healthy human lymphocytes

International Journal of Biochemistry and Cell Biology

Volumn 44, Issue 8, 2012, Pages 1223-1231

  Szabó Taylor, Katalin É ^a,c   Eggleton, Paul ^a   Turner, Carly A L ^a   Lo Faro, M Letizia ^a   Tarr, Joanna M ^a   Tóth, Sára ^c   Whiteman, Matt ^a   Haigh, Richard C ^a,b   Littlechild, Jennifer A ^a   Winyard, Paul G ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Autoimmune disease; Cell surface; Inflammation; Interleukin 17; Peroxiredoxin; Thioredoxin

Indexed keywords

INTERLEUKIN 17; PEROXIREDOXIN 2; PEROXIREDOXIN 3;

ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACELLULAR FLUID; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; INFLAMMATORY CELL; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; OXIDATION REDUCTION STATE; PROTEIN CONTENT; RHEUMATOID ARTHRITIS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; BLOTTING, WESTERN; EXTRACELLULAR FLUID; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-17; INTRACELLULAR FLUID; LYMPHOCYTES; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PEROXIREDOXIN III; PEROXIREDOXINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; THIOREDOXINS;

EID: 84861433598     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2012.04.016     Document Type: Article

References (51)

1. Angelini G, Gardella S, Ardy M, Ciriolo MR, Filomeni G, Di Trapani G, et al. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proceedings of the National Academy of Sciences 2002;99:1491-6. (Pubitemid 34136520)
2. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S. Type 17T helper cells - origins, features and possible roles in rheumatic disease. Nature Reviews Rheumatology 2009;5:325-31.
3. Arner ESJ, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. European Journal of Biochemistry 2000;267:6102-9.
4. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 1988;31:315-24. (Pubitemid 18091653)
5. Bashir S, Harris G, Denman MA, Blake DR, Winyard PG. Oxidative DNA damage and cellular sensitivity to oxidative stress in human autoimmune diseases. Annals of the Rheumatic Diseases 1993;52:659-66. (Pubitemid 23280435)
6. Baty JW, Hampton MB, Winterbourn CC. Proteomic detection of hydrogen peroxide-sensitive thiol proteins in Jurkat cells. Biochemical Journal 2005;389:785-95. (Pubitemid 41117338)
7. Bennett JC. The role of T lymphocytes in rheumatoid arthritis and other autoimmune diseases. Arthritis & Rheumatism 2008;58:S53-7. (Pubitemid 351281122)
8. Biteau B, Labarre J, Toledano MB. ATP-dependent reduction of cysteine-sulphinic acid by S. cerevisiae sulphiredoxin. Nature 2003;425:980-4. (Pubitemid 37376931)
9. Bo GP, Zhou LN, He WF, Luo GX, Jia XF, Gan CJ, et al. Analyses of differential proteome of human synovial fibroblasts obtained from arthritis. Clinical Rheumatology 2009;28:191-9.
10. Brown NS, Bicknell R. Hypoxia and oxidative stress in breast cancer: oxidative stress - its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Research 2001;3:323-7. (Pubitemid 32851163)
11. Budanov AV, Sablina AA, Feinstein E, Koonin AV, Chumakov PM. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 2004;304:596-600. (Pubitemid 38541920)
12. Chae HZ, Kim HJ, Kang SW, Rhee SG. Characterization of three isoforms of mammalian peroxiredoxin that reduce peroxides in the presence of thioredoxin. Diabetes Research and Clinical Practice 1999;45:101-12. (Pubitemid 29457756)
13. Choi M-H, Sajed D, Poole L, Hirata K, Herdman S, Torian BE, et al. An unusual surface peroxiredoxin protects invasive Entamoeba histolytica from oxidant attack. Molecular and Biochemical Parasitology 2005;143:80.
14. Cox AG, Pullar JM, Hughes G, Ledgerwood EC, Hampton MB. Oxidation of mitochondrial peroxiredoxin 3 during the initiation of receptor-mediated apoptosis. Free Radical Biology and Medicine 2008;44:1001-9.
15. Eggleton P, Harries LW, Alberigo G, Wordsworth P, Viner N, Haigh R, et al. Changes in apoptotic gene expression in lymphocytes from rheumatoid arthritis and systemic lupus erythematosus patients compared with healthy lymphocytes. Journal of Clinical Immunology 2010;30:649-58.
16. Gelderman KA, Hultqvist M, Holmberg J, Olofsson P, Holmdahl R. T cell surface redox levels determine T cell reactivity and arthritis susceptibility. Proceedings of the National Academy of Sciences 2006;103:12831-6. (Pubitemid 44298647)
17. Gilston V, Blake DR, Winyard PG. The rheumatoid joint: redox paradox? In: Montagnier L, Olivier R, Pasquier C, editors. Oxidative stress in cancer, AIDS, and neurodegenerative diseases. New York: Marcel Dekker Inc.; 1998. p. 517-35.
18. Griffiths HR, Dunston CR, Bennett SJ, Grant MM, Phillips DC, Kitas GD. Free radicals and redox signalling in T-cells during chronic inflammation and ageing. Biochemical Society Transactions 2011;39:1273-8.
19. Hakim AJ, Clunie GPR, Haq I. Oxford handbook of rheumatology. Oxford: Oxford University Press; 2006.
20. Hara T, Kondo N, Nakamura H, Okuyama H, Mitsui A, Hoshino Y, et al. Cell-surface thioredoxin-1: possible involvement in thiol-mediated leukocyteendothelial cell interaction through lipid rafts. Antioxidants and Redox Signalling 2007;9:1427-38.
21. Jikimoto T, Nishikubo Y, Koshiba M, Kanagawa S, Morinobu S, Morinobu A, et al. Thioredoxin as a biomarker for oxidative stress in patients with rheumatoid arthritis. Molecular Immunology 2001;38:765-72.
22. Kang SW, Rhee SG, Chang TS, Jeong W, Choi MH. 2-Cys peroxiredoxin function in intracellular signal transduction: therapeutic implications. Trends in Molecular Medicine 2005;11:571-8. (Pubitemid 41713999)
23. Kim CW, Cho EH, Lee YJ, Kim YH, Hah Y, Kim DR. Disease specific proteins from rheumatoid arthritis patients. Journal of Korean Medical Science 2006;21:478-84. (Pubitemid 43925994)
24. Kwon J, Devadas S, Williams MS. T cell receptor-stimulated generation of hydrogen peroxide inhibits MEK-ERK activation and lck serine phosphorylation. Free Radical Biology and Medicine 2003;35:406-17. (Pubitemid 37289170)
25. Lawrence DA, Song R, Weber P. Surface thiols of human lymphocytes and their changes after in vitro and in vivo activation. Journal of Leukocyte Biology 1996;60:611-8. (Pubitemid 26400418)
26. Lehtonen ST, Svensk AM, Soini Y, Pääkkö P, Hirvikoski P, Kang SW, et al. Peroxiredoxins a novel protein family in lung cancer. International Journal of Cancer 2004a;111:514-21. (Pubitemid 39045317)
27. Lehtonen ST, Svensk AM, Soini Y, Pääkkö P, Hirvikoski P, Kang SW, et al. A novel protein family in lung cancer. International Journal of Cancer 2004b;111:514-21. (Pubitemid 39045317)
28. Liu H, Pope RM. The role of apoptosis in rheumatoid arthritis. Current Opinion in Pharmacology 2003;3:317-22. (Pubitemid 36686774)
29. Martin H, Dean M. Identification of a thioredoxin-related protein associated with plasma membranes. Biochemical and Biophysical Research Communications 1991;175:123-8.
30. Maurice MM, Nakamura H, Gringhuis S, Okamoto T, Yoshida S, Kullmann F, et al. Expression of the thioredoxin-thioredoxin reductase system in the inflamed joints of patients with rheumatoid arthritis. Arthritis & Rheumatism 1999;42:2430-9. (Pubitemid 30333424)
31. Metcalfe C, Cresswell P, Ciaccia L, Thomas B, Barclay AN. Labile disulfide bonds are common at the leucocyte cell surface. Open Biology 2011;1:1-24.
32. Moon EY, Noh YW, Han YH, Kim SU, Kim JM, Yu DY, et al. T lymphocytes and dendritic cells are activated by the deletion of peroxiredoxin II (Prx II) gene. Immunology Letters 2006;102:184-90.
33. Mougiakakos D, Johansson CC, Jitschin R, Böttcher M, Kiessling R. Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress. Blood 2011;117:857-61.
34. Mougiakakos D, Johansson CC, Kiessling R. Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death. Blood 2009;113:3542-5.
35. Pattison DJ, Winyard PG. Dietary antioxidants in inflammatory arthritis: do they have any role in etiology or therapy. Nature Clinical Practice Rheumatology 2008;4:590-6.
36. Pedersen-Lane JH, Zurier RB, Lawrence DA. Analysis of the thiol status of peripheral blood leukocytes in rheumatoid arthritis patients. Journal of Leukocyte Biology 2007;81:934-41. (Pubitemid 46495642)
37. Peskin AV, Low FM, Paton LN, Maghzal GJ, Hampton MB, Winterbourn CC. The high reactivity of peroxiredoxin 2 with H2O2 is not reflected in its reaction with other oxidants ad thiol reagents. Journal of Biological Chemistry 2007;282:11885-92. (Pubitemid 47100684)
38. Sahaf B, Söderberg A, Spyrou G, Barral AM, Pekkari K, Holmgren A, et al. Thioredoxin expression and localization in human cell lines: detection of full-length and truncated species. Experimental Cell Research 1997;236:181-92. (Pubitemid 27452362)
39. Schröder E, Littlechild JA, Lebedev AA, Errington N, Vagin AA, Isupov MN. Crystal structure of decameric 2-Cys peroxiredoxin from human erythrocytes at 1.7 Å resolution. Structure 2000;8:605-15. (Pubitemid 30409313)
40. Seo MS, Kang SW, Kim K, Baines IC, Lee TH, Rhee SG. Identification of a new type of mammalian peroxiredoxin that forms an intramolecular disulfide as a reaction intermediate. Journal of Biological Chemistry 2000;275:20346-54. (Pubitemid 30457609)
41. Szabó KÉ, Line K, Eggleton P, Littlechild JA, Winyard PG. Structure and function of the human peroxiredoxin-based antioxidant system: the interplay between peroxiredoxins, thioredoxins, thioredoxin reductases, sulfiredoxins and sestrins. In: Winyard PG, Jacob C, editors. Redox signalling and regulation in biology and medicine. Weinheim: Wiley-VCH; 2009. p. 143-79.
42. Tarr JM, Winyard PG, Ryan B, Harries LW, Haigh R, Viner N, et al. Extracellular calreticulin is present in the joints of rheumatoid arthritis patients and inhibits FasL (CD95L) mediated apoptosis of T cells. Arthritis & Rheumatism 2010;62:2919-29.
43. Wang MX, Wei A, Yuan J, Trickett A, Knoops B, Murrell GAC. Expression and regulation of peroxiredoxin 5 in human osteoarthritis. FEBS Letters 2002;531:359.
44. Wang T, Tamae D, LeBon T, Shively JE, Yen Y, Li JJ. The role of peroxiredoxin II in radiation-resistant MCF-7 breast cancer cells. Cancer Research 2005;65:10338-46. (Pubitemid 41748145)
45. Wollman EE, Kahan A, Fradelizi D. Detection of membrane associated thioredoxin on human cell lines. Biochemical and Biophysical Research Communications 1997;230:602-6. (Pubitemid 27225583)
46. Wood ZA, Poole LB, Karplus PA. Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling. Science 2003a;300:650-3. (Pubitemid 36520591)
47. Wood ZA, Schröder E, Harris JR, Poole LB. Structure, mechanism and regulation of peroxiredoxins. Trends in Biochemical Sciences 2003b;28:32-40. (Pubitemid 36051004)
48. Yan Z, Banerjee R. Redox remodeling as an immunoregulatory strategy. Biochemistry 2010;49:1059-66.
49. Yang CS, Lee DS, Song CH, An SJ, Li S, Kim JM, et al. Roles of peroxiredoxin II in the regulation of proinflammatory responses to LPS and protection against endotoxin-induced lethal shock. Journal of Experimental Medicine 2007;204:583-94. (Pubitemid 46457081)
50. Yoshida S, Katoh T, Tetsuka T, Uno K, Matsui N, Okamoto T. Involvement of thioredoxin in rheumatoid arthritis: its costimulatory roles in the TNF-α-induced production of IL-6 and IL-8 from cultured synovial fibroblasts. Journal of Immunology 1999;163:351-8. (Pubitemid 29295860)
51. Zhang P, Liu B, Kang S, Seo M, Rhee S, Obeid L. Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2. Journal of Biological Chemistry 1997;272:30615-8. (Pubitemid 27527491)